74 related articles for article (PubMed ID: 28949050)
1. Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome.
Ueda Y; Ogura M; Miyakoshi S; Suzuki T; Heike Y; Tagashira S; Tsuchiya S; Ohyashiki K; Miyazaki Y
Cancer Sci; 2017 Dec; 108(12):2445-2453. PubMed ID: 28949050
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.
Spira A; Hansen AR; Harb WA; Curtis KK; Koga-Yamakawa E; Origuchi M; Li Z; Ertik B; Shaib WL
Target Oncol; 2021 Jul; 16(4):461-469. PubMed ID: 33939067
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Maslak PG; Dao T; Bernal Y; Chanel SM; Zhang R; Frattini M; Rosenblat T; Jurcic JG; Brentjens RJ; Arcila ME; Rampal R; Park JH; Douer D; Katz L; Sarlis N; Tallman MS; Scheinberg DA
Blood Adv; 2018 Feb; 2(3):224-234. PubMed ID: 29386195
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission.
Manning-Geist BL; Gnjatic S; Aghajanian C; Konner J; Kim SH; Sarasohn D; Soldan K; Tew WP; Sarlis NJ; Zamarin D; Kravetz S; Laface I; Rasalan-Ho T; Qi J; Wong P; Sabbatini PJ; O'Cearbhaill RE
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900251
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
[TBL] [Abstract][Full Text] [Related]
8. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
10. Decade-long WT1-specific CTLs induced by WT1 peptide vaccination.
Suwabe T; Shibasaki Y; Tamura S; Katagiri T; Fuse K; Ida-Kurasaki T; Ushiki T; Sone H; Narita M; Masuko M
Int J Hematol; 2024 Apr; 119(4):399-406. PubMed ID: 38427208
[TBL] [Abstract][Full Text] [Related]
11. Vaccines: a promising therapy for myelodysplastic syndrome.
Gera K; Chauhan A; Castillo P; Rahman M; Mathavan A; Mathavan A; Oganda-Rivas E; Elliott L; Wingard JR; Sayour EJ
J Hematol Oncol; 2024 Jan; 17(1):4. PubMed ID: 38191498
[TBL] [Abstract][Full Text] [Related]
12. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.
Ueki H; Kitagawa K; Kato M; Yanase S; Okamura Y; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M; Shirakawa T
Sci Rep; 2023 Jun; 13(1):9994. PubMed ID: 37340017
[TBL] [Abstract][Full Text] [Related]
13. The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.
Peng X; Zhu X; Di T; Tang F; Guo X; Liu Y; Bai J; Li Y; Li L; Zhang L
Front Immunol; 2022; 13():994053. PubMed ID: 36211357
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes.
Ueda Y; Usuki K; Fujita J; Matsumura I; Aotsuka N; Sekiguchi N; Nakazato T; Iwasaki H; Takahara-Matsubara M; Sugimoto S; Goto M; Naoe T; Kizaki M; Miyazaki Y; Aakashi K
Cancer Sci; 2022 Apr; 113(4):1377-1392. PubMed ID: 34932235
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.
Holmberg-Thydén S; Dufva IH; Gang AO; Breinholt MF; Schejbel L; Andersen MK; Kadivar M; Svane IM; Grønbæk K; Hadrup SR; El Fassi D
Cancer Immunol Immunother; 2022 Feb; 71(2):433-444. PubMed ID: 34218294
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in AML: a brief review on emerging strategies.
Moeinafshar A; Hemmati S; Rezaei N
Clin Transl Oncol; 2021 Dec; 23(12):2431-2447. PubMed ID: 34160771
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms.
Chen J; Zhang H; Zhou L; Hu Y; Li M; He Y; Li Y
Front Oncol; 2020; 10():584367. PubMed ID: 33614478
[TBL] [Abstract][Full Text] [Related]
18. Vaccine Therapies for Cancer: Then and Now.
Morse MA; Gwin WR; Mitchell DA
Target Oncol; 2021 Mar; 16(2):121-152. PubMed ID: 33512679
[TBL] [Abstract][Full Text] [Related]
19. WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.
Suwabe T; Shibasaki Y; Sato H; Tamura S; Katagiri T; Nemoto H; Kasami T; Kozakai T; Nanba A; Kitajima T; Fuse K; Ushiki T; Sone H; Narita M; Masuko M
Int J Hematol; 2021 May; 113(5):723-734. PubMed ID: 33502734
[TBL] [Abstract][Full Text] [Related]
20. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.
Nishida S; Tsuboi A; Tanemura A; Ito T; Nakajima H; Shirakata T; Morimoto S; Fujiki F; Hosen N; Oji Y; Kumanogoh A; Kawase I; Oka Y; Azuma I; Morita S; Sugiyama H
Medicine (Baltimore); 2019 Aug; 98(33):e16771. PubMed ID: 31415377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
